Alpha Cognition Inc.

Company Overview

Business Model: Alpha Cognition Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative diseases, primarily Alzheimer’s disease. Its core value proposition revolves around ZUNVEYL, an FDA-approved next-generation acetylcholinesterase inhibitor designed for mild-to-moderate Alzheimer’s disease with expected minimal gastrointestinal side effects. The company generates revenue through product sales of ZUNVEYL and licensing arrangements for its intellectual property.

Market Position: Alpha Cognition Inc. has recently entered the U.S. Alzheimer’s long-term care (LTC) market, which represents a significant portion (36%) of the over 11 million annual acetylcholinesterase inhibitor (AChEI) prescriptions. ZUNVEYL is positioned to differentiate itself from existing AChEI treatments (such as donepezil, rivastigmine, and galantamine) by offering established galantamine efficacy with cognitive benefits, clinical data demonstrating reduced gastrointestinal side effects, a dual mechanism of action, an enteric-coated tablet formulation, and no reported incidence of insomnia in its FDA-approved label. Market research indicates an 88% likelihood of LTC prescriber adoption with a 29% preference share for ZUNVEYL. The company also has pre-clinical programs for moderate-to-severe Alzheimer’s disease and cognitive impairment with mild traumatic brain injury (mTBI).

Recent Strategic Developments:

• Commercial Launch: Officially launched ZUNVEYL on March 19, 2025, targeting the U.S. LTC market with a specialized sales force.
• FDA Approval: ZUNVEYL received FDA approval for mild-to-moderate Alzheimer’s disease on July 26, 2024.
• International Licensing: On January 8, 2025, entered an exclusive licensing agreement with CMS International Development and Management Limited for ZUNVEYL in Asia (excluding Japan), Australia, and New Zealand, totaling $44 million in upfront, development, and commercial milestone payments, plus royalties.
• Key Hires: In January 2025, made strategic appointments to its commercial and medical teams, including Vice President of Commercial, Head of Market Access, Vice President of Corporate Strategy and Operations, and Vice President of Medical Affairs.
• Pipeline Reversion: Exercised a reversion of rights for ALPHA-1062 for TBI, pancreatitis, and related conditions in January 2025, bringing these compounds back for internal development.
• Asset Termination: Terminated licensing agreements for pre-clinical assets ALPHA-0602, ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s), retaining certain royalties and payments from the licensor.

Geographic Footprint: Alpha Cognition Inc. operates primarily in the United States and Canada, with virtual offices in Vancouver, British Columbia, and Grapevine, Texas. Manufacturing of ZUNVEYL's active pharmaceutical ingredient is conducted in Taiwan, and oral tablet and nasal spray formulations are produced in the United States. Clinical trials have been conducted in India and the Netherlands. Commercialization efforts are focused on the U.S. LTC market, with strategic partnerships sought for distribution in Europe, LATAM (Mexico, Central and South America), the Middle East, and Asia (excluding Japan), Australia, and New Zealand.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 81.26%
• Operating Margin: -221.72%
• Net Margin: -202.24%

Investment in Growth (2025):

• R&D Expenditure: $1.9 million (18.28% of revenue)
• Capital Expenditures: $0.3 million (primarily computer equipment and software)
• Strategic Investments: Approximately $15.3 million of net proceeds from public offerings were allocated to commercialization and launch of ZUNVEYL, and $4.0 million for continued commercial Chemistry, Manufacturing, and Controls (CMC) activities.

Business Segment Analysis

Alpha Cognition Inc.'s Chief Executive Officer views the company's operations and manages its business as a single reportable operating segment, focusing on the commercial manufacturing and sales of pharmaceutical treatments for neurological diseases in Canada and the United States.

ZUNVEYL (Mild-to-Moderate Alzheimer’s Disease)

Financial Performance:

• Revenue: $6.8 million (Product sales, net) in 2025.
• Operating Margin: Not directly calculable for this specific product, but contributes to the overall company's -221.72% operating margin.
• Key Growth Drivers: Commercial launch in March 2025, targeting the U.S. long-term care market (36% of AChEI prescriptions), leveraging an account-based sales team, securing formulary coverage with U.S. payors, and negotiating agreements with pharmacy benefit managers. The Wholesale Acquisition Cost (WAC) is set at $820 per month.

Product Portfolio:

• ZUNVEYL oral tablet formulation (benzgalantamine), a next-generation acetylcholinesterase inhibitor.
• New product launches or major updates: Official commercial launch on March 19, 2025.

Market Dynamics:

• Competitive positioning within segment: Differentiated from existing generic AChEI treatments (donepezil, rivastigmine, galantamine) and branded products (Adlarity, Namzaric) by its expected minimal gastrointestinal side effects, dual mechanism of action (binding neuronal nicotinic receptors, notably alpha-7 subtype), and enteric-coated tablet.
• Key customer types and market trends: Focus on long-term care physicians in nursing homes. High patient turnover (30% by month 4, 55% by one year) with existing AChEI medications presents an opportunity for ZUNVEYL. Disease-modifying treatments (DMTs) like Leqembi are not considered direct competitors as they are used in combination with symptomatic treatments.

ZUNVEYL in combination with memantine (Moderate-to-Severe Alzheimer’s Disease)

Financial Performance: Pre-clinical development, no revenue. Product Portfolio: Combination oral product of benzgalantamine and memantine. Market Dynamics: Targets ~1.4 million patients in the U.S. with moderate-to-severe Alzheimer’s disease. Aims to simplify co-administration, improve compliance, and offer differentiating efficacy and tolerability. Plans to leverage existing ZUNVEYL sales force for LTC providers.

ALPHA-1062 Sublingual Formulation (Dysphagia and Mild Traumatic Brain Injury (mTBI))

Financial Performance: Pre-clinical development, no revenue. Product Portfolio: Sublingual formulation of ALPHA-1062. Market Dynamics:

• Dysphagia: Targets Alzheimer’s patients suffering from dysphagia (inability to swallow), estimated at over 80% of moderate to severe patients. In vitro studies showed active drug release in 30 seconds, and a single-dose study demonstrated 90% bioavailability and good tolerability.
• mTBI: Pre-clinical studies showed ALPHA-1062 significantly reduced motor deficit, improved motor and sensory functional recovery, and improved cognitive functional recovery in animal models. The addressable market for cognitive impairment with mTBI is estimated at 1.1 million patients per year in the U.S., with a potential market size of $13.5 billion. No approved acute or chronic treatments for TBI currently exist.

ALPHA-0602, ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s)

Financial Performance: No revenue. Product Portfolio: Previously pre-clinical assets for neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). Market Dynamics: The company terminated its licensing agreement related to these assets as they did not add material value, but retained certain royalties and payments from the licensor for any future developments.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None reported for the fiscal year ended December 31, 2025.
• Dividend Payments: Alpha Cognition Inc. has paid no dividends on common stock to date and does not expect to pay dividends in the foreseeable future, intending to invest future earnings in growth.
• Future Capital Return Commitments: The company entered into an At the Market Offering Agreement in August 2025, allowing it to sell up to $75.0 million in common stock, though this facility was not utilized as of December 31, 2025.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $66.1 million (including restricted cash).
• Total Debt: $0 (promissory note and convertible debentures were repaid or converted in 2025 and 2024, respectively).
• Net Cash Position: $66.1 million.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: No outstanding debt as of December 31, 2025.

Cash Flow Generation (Year Ended December 31, 2025):

• Operating Cash Flow: -$20.4 million (increased outflow by $12.6 million YoY, driven by higher API purchases, manufacturing, employee costs, and commercial/marketing expenses).
• Free Cash Flow: -$20.7 million (Operating Cash Flow less Capital Expenditures).
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Alpha Cognition Inc. relies on specialized contract manufacturing organizations (CMOs) for the production of its product candidates. The ZUNVEYL active pharmaceutical ingredient (API) is manufactured in Taiwan, while oral tablets and nasal spray formulations are produced by manufacturing companies in the United States. The company plans to contract with back-up API and CMOs to mitigate supply disruption risks.

Supply Chain Architecture: Key Suppliers & Partners:

• API Manufacturing: Single vendor in Taiwan for ZUNVEYL's active pharmaceutical ingredient.
• Drug Product Manufacturing: Single vendor in the United States for ZUNVEYL oral tablets and nasal spray formulations.
• Clinical Research Organizations (CROs): Vimta Labs, Inc. (India) for bioavailability and bioequivalence trials; Centre for Human Disease Research (CHDR) (Netherlands) for Phase 1 studies.
• Regulatory Consultants: Engaged to advise and assist with FDA and European Medicines Agency (EMA) submissions.

Facility Network:

• Manufacturing: Relies on third-party CMOs in Taiwan (API) and the United States (oral tablets/nasal spray).
• Research & Development: Conducts pre-clinical studies and clinical trials through CROs.
• Distribution: Plans to identify pharmaceutical distribution partners for major international territories (Europe, LATAM, Middle East, Asia).

Operational Metrics: The company has demonstrated required stability endpoints for twelve months of long-term stability data for ZUNVEYL delayed release oral tablet formulation in three potential strengths.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Established a specialty sales force focused on long-term care (LTC) physicians in the U.S. who treat elderly patients in nursing homes.
• Channel Partners: Actively engaged in securing formulary coverage for ZUNVEYL with U.S. payors and negotiating agreements with pharmacy benefit managers (PBMs). As of the report date, agreements have been executed with two of the four major national PBMs. Intends to seek strategic partnerships for international distribution in Europe, LATAM, Middle East, and Asia (excluding Japan), Australia, and New Zealand.
• Digital Platforms: Plans to deploy a targeted multi-channel market campaign for caregivers, including website education.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Targets largest volume nursing homes specializing in Alzheimer’s Disease.
• Strategic Partnerships: Developing strategic and clinical partnerships with consultant pharmacists and long-term care pharmacies.
• Customer Concentration: As of December 31, 2025, three customers accounted for approximately 48%, 22%, and 17% of total revenue, and 60%, 17%, and 19% of accounts receivable, respectively.

Geographic Revenue Distribution (Year Ended December 31, 2025):

• United States: 66.46% of total revenue ($6,792,024 from product sales).
• China: 33.54% of total revenue ($3,428,251 from licensing).
• Growth Markets: Actively seeking distribution partners for Europe, LATAM, Middle East, and other Asian countries.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The neurodegenerative disease market, particularly Alzheimer's disease, is characterized by limited treatment options, perceived limited symptom improvement, and difficult-to-manage tolerability side effects with existing symptomatic treatments. It is a highly genericized market with limited drug development innovation. The U.S. Alzheimer's LTC market is valued at $2 billion. The mTBI market has no current acute or chronic approved treatments, with an estimated 1.1 million adult patients per year suffering from cognitive impairment, representing a potential $13.5 billion market size in the U.S.

Competitive Positioning Matrix (ZUNVEYL for Mild-to-Moderate Alzheimer's Disease):

Direct Competitors

Primary Competitors (Alzheimer's Disease Symptomatic Treatments):

• Donepezil (Aricept, Adlarity, generics): First-to-market (1996), generic, oral tablet/transdermal patch, 70% market share.
• Rivastigmine (Exelon, generics): Approved 2000, generic, capsules/patch, 4.86% market share.
• Galantamine (Reminyl, Razadyne, generics): Approved 2001, generic, oral solution/tablet/extended-release capsules, 2.27% market share.
• Memantine (Namenda, Namzaric, generics): NMDA receptor agonist, used for moderate-to-severe AD, often in combination. Namzaric (AbbVie) is a branded combination.
• Adlarity (Corium): Transdermal donepezil, approved March 2022.

Primary Competitors (Alzheimer's Disease Modifying Treatments - DMTs):

• Aducanumab (Adulhelm by Biogen): Received accelerated approval in 2021, but discontinued by end of 2024 due to access issues.
• Lecanemab (Leqembi by Eisai): Indicated for Alzheimer's disease, expected better coverage than Aducanumab, but not a direct competitor to AChEI class as it addresses disease modification, not symptoms.

Primary Competitors (mTBI - in clinical trials):

• Vasopharm
• SanBio/Sumitomo
• Otsuka/Avanir Pharmaceuticals
• Biogen
• Cellvation

Emerging Competitive Threats: New therapies and combinations, technologies, and data emerging in the CNS field. Many competitors have greater financial resources and expertise.

Competitive Response Strategy: Alpha Cognition Inc. aims to differentiate ZUNVEYL through its unique product attributes (reduced GI side effects, dual mechanism, no insomnia) and target the unmet needs of patients who discontinue current treatments. For its combination therapy, it plans to highlight differentiating efficacy and tolerability. For mTBI, it aims to address the high unmet need with no currently approved treatments. The company also seeks strategic partnerships to expand promotional efforts and market reach.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Commercial Adoption: ZUNVEYL may fail to achieve broad adoption by physicians, patients, and payors, limiting revenue generation.
• Market Size: Estimated market opportunities for ZUNVEYL may be smaller than anticipated, requiring approval for additional indications to achieve profitability.
• Competition: Significant competition from larger pharmaceutical companies, academic institutions, and other biopharmaceutical companies with greater resources and expertise. Competitors may develop safer, more effective, or cheaper therapies.
• Pipeline Expansion: Inability to successfully identify, develop, in-license, or acquire additional product candidates could impair business expansion.
• Alzheimer's Disease Development Challenges: Historically low success rates in Alzheimer's drug development (e.g., Aducanumab discontinuation).

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Reliance on a single Taiwan-based vendor for API and a single U.S.-based vendor for manufacturing ZUNVEYL. Loss of these suppliers or their failure to comply with regulatory requirements could materially affect the business.
• Geographic Concentration: Manufacturing in Taiwan exposes the company to risks from foreign economic downturns, political instability, and geopolitical tensions (e.g., China-Taiwan instability).
• Capacity Constraints: Product candidates have not been manufactured on a commercial scale, and scaling up manufacturing involves risks of cost overruns, process reproducibility issues, and timely raw material availability.
• Manufacturing Complexity: Drug manufacturing is complex; deviations or difficulties could delay supply for clinical trials or commercialization.
• Third-Party Reliance: Dependence on Contract Research Organizations (CROs) for clinical trials; failure to perform duties or meet deadlines could delay regulatory approval.

Financial & Regulatory Risks

Market & Financial Risks:

• Operating Losses: History of significant net losses ($20.7 million in 2025); expects to incur substantial losses for the foreseeable future.
• Capital Requirements: Will need substantial additional capital beyond the next 12 months to fund operations, commercialization, and R&D. Inability to raise capital could force delays or elimination of programs.
• Currency Fluctuations: Exposure to fluctuations in currency exchange rates (USD, CAD, EUR) due to expenses and royalty payments in foreign currencies.
• Product Liability: Inherent risk of product liability lawsuits from clinical testing and commercialization, potentially leading to substantial liabilities, limited commercialization, or reputational harm.
• Information Systems & Data Security: Vulnerability to cyber threats, data breaches, and system disruptions, which could lead to operational interruptions, data loss, regulatory scrutiny, and financial penalties.
• Internal Control Weaknesses: Identified material weaknesses in internal control over financial reporting (e.g., accounting for warrants and stock option liabilities, segregation of duties), which could impair timely and accurate financial reporting.

Regulatory & Compliance Risks:

• Regulatory Approval Process: Lengthy, time-consuming, and unpredictable regulatory approval processes by the FDA and foreign authorities. No guarantee of approval for other product candidates.
• Post-Approval Scrutiny: ZUNVEYL remains subject to ongoing regulatory requirements (manufacturing, labeling, promotion, safety monitoring, post-market studies). Failure to comply could lead to enforcement actions or withdrawal of approval.
• Data Acceptance: FDA and foreign authorities may not accept data from clinical trials conducted outside their jurisdictions, requiring additional costly and time-consuming trials.
• Healthcare Legislation: Unfavorable pricing regulations or healthcare reform initiatives (e.g., ACA changes, drug pricing scrutiny) could increase costs and limit commercial potential.
• Healthcare Regulatory Laws: Business operations subject to fraud and abuse, data privacy (HIPAA, CCPA, GDPR), anti-kickback, and anti-corruption laws, exposing the company to penalties for non-compliance.
• Government Agency Funding: Disruptions at the FDA and other government agencies due to funding shortages or global health concerns could delay product development and approval.

Geopolitical & External Risks

Geopolitical Exposure:

• Taiwan Manufacturing: Dependence on Taiwan for API manufacturing exposes the company to risks from China-Taiwan geopolitical instability, potentially disrupting supply.
• Global Economic Conditions: Unfavorable global economic or political conditions (e.g., Russia-Ukraine conflict, Middle East tensions) could affect capital markets, supply chains, and overall business.
• Climate Change & Natural Disasters: Risks from natural disasters, power disruptions, or terrorism affecting personnel, data centers, supply chain, and manufacturing.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• ZUNVEYL (ALPHA-1062): A next-generation acetylcholinesterase inhibitor for Alzheimer's disease, differentiated by its active metabolite binding neuronal nicotinic receptors (alpha-7 subtype) and expected minimal gastrointestinal side effects.
• ALPHA-1062 + Memantine: A combination oral product in pre-clinical development for moderate-to-severe Alzheimer's disease, aiming for triple mechanism of action (acetylcholinesterase inhibition, enhanced nicotinic receptor activity, NMDA receptor antagonism).
• ALPHA-1062 Sublingual Formulation: In early development for patients with dysphagia and for cognitive impairment with mild traumatic brain injury (mTBI).
• Progranulin (ALPHA-0602, ALPHA-0702 & ALPHA-0802): Previously focused on neurodegenerative diseases like ALS and SMA, but licensing agreement terminated, with royalties retained.
• Innovation Pipeline: Focused on advancing ZUNVEYL for additional indications and new products, and pursuing pre-clinical assets when timing is appropriate.

Intellectual Property Portfolio: Alpha Cognition Inc. has developed, filed, and exclusively licensed a significant intellectual property portfolio for ZUNVEYL (ALPHA-1062) and ALPHA-1062IN.

• Patent Strategy: Builds on therapeutic use patents by avoiding traditional fast-release oral/transdermal routes to preserve the pro-portion of ALPHA-1062. Focuses on delivery, polymorph, and formulation patents to extend effective patent protection.
• Patent Holdings:
  • Blood Brain Barrier II (BBB II): Therapeutic use patents for neurological diseases with cholinergic deficit. US patents granted (US 9,763,953 expiring 12/1/2026, US 10,265,325 expiring 09/22/2026), China patent granted (CN 102007129 expiring 04/14/2028). Patent term extension filed for US 9,763,953.
  • Blood Brain Barrier III (BBB III): Enhanced bioavailability of galantamine by selected formulations and trans-mucosal routes. US patent granted (US11,077,119 expiring 08/07/2033) for sublingual administration.
  • Blood Brain Barrier IV (BBB IV): Self-preserving compositions and multi-use dispensers for ALPHA-1062 (anti-microbial properties). Applications pending in US, China, Hong Kong, Europe (estimated expiry 05/14/2041).
  • Blood Brain Barrier V (BBB V): Solid Forms of ALPHA-1062 Gluconate (stable, highly soluble polymorph). US patents granted (US 11,795,176, 12,157,743 expiring 01/13/2042), with further US continuation applications filed. Applications pending in Europe, Singapore, Russia, Mexico, Korea, Japan, Israel, China, Hong Kong, Canada, Brazil, Australia.
  • Blood Brain Barrier VI (BBB VI): ALPHA-1062 for Treating Traumatic Brain Injury (TBI). US application allowed (est. 11/25/2042), further US continuation filed. Applications pending in Japan, Europe, China, Canada, Australia, Hong Kong.
  • Blood Brain Barrier VII (BBB VII): ALPHA-1062 for Treating Post Concussive Syndrome (PCS). Applications filed in Europe, China, United States (est. 5/24/2044).
  • Blood Brain Barrier VIII (BBB VIII): Coated tablets for pH-dependent release of benzgalantamine. US patent granted (US 12,208,167 est. 02/06/2044), US continuation filed. Applications pending in China, Taiwan, Hong Kong.
  • Blood Brain Barrier IX (BBB IX): Process for Preparing Benzgalantamine and Salts Thereof. US priority application and China application filed (est. 03/25/2045, 03/31/2045).
  • Blood Brain Barrier X (BBB X): Methods of Achieving Specific Pharmacokinetic Effects for Galantamine. US priority application filed (est. 07/23/2045).
  • Blood Brain Barrier XI (BBB XI): Dosage Regimens for Benzgalantamine. US patent granted (US 12,551,491 est. 07/23/2045).
  • Blood Brain Barrier XII (BBB XII): Amorphous solid form of Benzgalantamine gluconate. US priority application filed (est. 12/19/2045).
• Licensing Programs: Exclusive licensing agreement with CMS International Development and Management Limited for ZUNVEYL in Asia (excluding Japan), Australia, and New Zealand.
• IP Litigation: No material litigation disclosed.

Technology Partnerships:

• Neurodyn Life Sciences Inc. (NLS): Original licensor of ALPHA-1062 Technology.
• CMS International Development and Management Limited (CMSI): Exclusive licensee for ZUNVEYL in Asia (excluding Japan), Australia, and New Zealand.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company is dependent on its senior management, particularly the CEO, Michael McFadden, and senior scientists. It faces significant competition for experienced personnel.

Board Composition: The filing lists Michael McFadden, Len Mertz, Kenneth Cawkell, Robert Wills, Phillip Mertz, and Rajeev Bakshi as Directors. Further details on independence, expertise areas, or committee structure are not explicitly disclosed in the provided text.

Human Capital Strategy

Workforce Composition:

• Total Employees: 71 full-time employees as of December 31, 2025 (72 full-time employees and 1 part-time contractor as of March 30, 2026).
• Geographic Distribution: Employees work virtually in offices located in Vancouver, British Columbia, and Dallas/Fort Worth, Texas.
• Skill Mix: The company needs to expand managerial, operational, finance, clinical, manufacturing, and scientific resources to manage growth and commercialization.

Talent Management: Acquisition & Retention: The company faces intense competition for qualified personnel in the biopharmaceutical field. It relies on stock awards as part of its employee value proposition.

• Hiring Strategy: Focus on attracting and retaining highly qualified management, clinical, and scientific personnel.
• Retention Metrics: Not explicitly disclosed, but high turnover in the industry is noted as a risk.
• Employee Value Proposition: Compensation philosophy includes stock awards.

Diversity & Development: Not explicitly disclosed in the provided text.

Environmental & Social Impact

Environmental Commitments: Not explicitly disclosed in the provided text.

Supply Chain Sustainability: Not explicitly disclosed in the provided text.

Social Impact Initiatives: Not explicitly disclosed in the provided text.

Business Cyclicality & Seasonality

Demand Patterns: Alpha Cognition Inc.'s business is not expected to be cyclical or seasonal. Economic Sensitivity: The business is susceptible to general conditions in the global economy and financial markets, including volatility from global financial crises or political disruptions. Industry Cycles: Not explicitly disclosed beyond general economic sensitivity.

Planning & Forecasting: Not explicitly disclosed in the provided text.

Regulatory Environment & Compliance

Regulatory Framework: Alpha Cognition Inc. operates in a highly regulated industry, subject to extensive government regulation in the United States (FDA) and other countries, covering research, development, testing, manufacturing, approval, labeling, marketing, and distribution of pharmaceutical products.

• Industry-Specific Regulations: Compliance with the federal Food, Drug, and Cosmetic Act (FDCA), Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and current Good Manufacturing Practice (cGMP) requirements.
• International Compliance: Requires separate marketing approvals and compliance with numerous and varying regulatory requirements in foreign jurisdictions (e.g., European Medicines Agency (EMA)).
• Post-Approval Requirements: ZUNVEYL is subject to ongoing regulatory requirements for manufacturing, labeling, advertising, promotion, safety monitoring, and post-market studies. The FDA required further root cause investigation into high variability of ZUNVEYL dissolution data and development of new dissolution methods by February 28, 2025.
• Expedited Pathways: May explore accelerated approval pathways (e.g., fast track, priority review, accelerated approval, breakthrough therapy designation) for product candidates in areas of high unmet need.
• Marketing Exclusivity: ZUNVEYL did not receive any FDA exclusivity associated with its NDA approval.
• Healthcare Laws: Subject to U.S. federal anti-kickback, anti-self-referral, false claims, transparency (Physician Payments Sunshine Act), consumer fraud, pricing reporting, data privacy (HIPAA, HITETECH, CCPA, CPRA), and anti-corruption laws (FCPA), as well as similar state and foreign laws.

Trade & Export Controls:

• Export Restrictions: Subject to U.S. and certain foreign export and import controls, sanctions, and embargoes.
• Sanctions Compliance: Compliance with sanctions and export controls imposed by the U.S. or United Nations.

Legal Proceedings: Alpha Cognition Inc. is not currently a party to any material legal proceedings nor aware of any contemplated by government agencies.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 0.0% for the year ended December 31, 2025, due to operating losses and a full valuation allowance against deferred tax assets.
• Geographic Tax Planning: Subject to income taxes in the United States (federal and various state jurisdictions) and Canada.
• Tax Reform Impact: The Inflation Reduction Act of 2022 impacts U.S. federal income taxation of corporations, including a minimum tax on book income and an excise tax on stock repurchases. The company cannot predict the full impact of this or future tax law changes.
• Net Operating Losses (NOLs): As of December 31, 2025, had Canadian non-capital losses of approximately $57 million (expiring 2035-2045) and U.S. federal NOLs of $11 million (expiring 2042). Utilization of NOLs may be subject to limitations under Section 382 of the U.S. Tax Code or subsection 111(5) of the Canadian Tax Act due to ownership changes.

Insurance & Risk Transfer

Risk Management Framework: Alpha Cognition Inc. has implemented and maintains various information security processes, leveraging a third-party service provider under the direction of its Chief Financial Officer, to identify, assess, and manage cybersecurity threats and risks to its information systems and data. The audit committee of the board of directors oversees cybersecurity risk management.

• Insurance Coverage: Carries product liability insurance for clinical trials and maintains cybersecurity insurance. Plans to expand product liability insurance to cover commercial sales upon marketing approval.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.